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What is already known about this topic? 
 
 Costs within a UK healthcare context and health utilities for Motor Neurone Disease 
(MND) are not well documented; neither are their association with well-defined health 
states. 
 
What does the paper add to existing knowledge? 
 
 This paper uses two well established health staging systems – Kings and MiToS – on a 
large, representative cohort of patients with MND, to characterise the health state 
utilities and costs associated with MND. 
 
What insights does the paper provide for informing health care related decision making?  
 
 The results demonstrate the discriminatory value of MND staging systems in relation to 
health utilities and healthcare costs. Mean EQ-5D-5L utilities decreased and costs 




Background: Motor Neurone Disease (MND) places a significant burden on patients, their 
carers and healthcare systems. However, there is limited information on health utilities and 
costs within a United Kingdom setting.   
 
Methods: Patients with MND, recruited via 22 regional clinics, completed a postal 
questionnaire of a cost and quality of life survey. Health outcome assessment included the 
EQ-5D-5L, EQ-VAS, ALS Utility Index and the Amyotrophic Lateral Sclerosis Functional Rating 
Scale - Revised. Clinical staging was based on the Kings and MiToS systems. The 
questionnaire asked about patients’ use of primary, secondary and community care services 
in the previous 3-months. Variability in total costs was examined using regression models.  
 
Results: 595 patients were included in the health utility analysis, of whom 584 patients also 
completed a resource use questionnaire. Mean health utility decreased and costs increased 
between consecutive Kings stages, from 0.76 (95%CI 0.71, 0.80) and £1,096 (£757, £1,240) 
in Kings stage 1, to 0.50 (0.45, 0.54) and £3,311 (£2,666, £4,151) in stage 4, respectively. The 
changes by MiToS stages, were from 0.71 (0.69, 0.73) and £1,115 (£937, £1,130) in MiToS 
stage 0, to 0.25 (0.07, 0.42) and £2,899 (£2,190, £3,840) in stage 2. Kings stages 3 and 4, and 
MiToS Stages 1 and 2, respectively, were significant in explaining variability in total costs. 
 
Conclusions: The impact of MND on health utilities and costs differs by disease severity. The 
data provided here can be used in cost-effectiveness analyses and to inform decision-





Motor Neurone Disease (MND) (or amyotrophic lateral sclerosis) is a neurodegenerative 
condition associated with extensive impairment of patients’ mobility, communication and 
breathing which results in large reductions in their health-related quality of life [1]. The 
average life expectancy is only 3 -5 years from disease onset [2], and treatment is focused 
on symptom management, slowing disease progression and providing palliative care. MND 
incurs significant financial burden on patients, caregivers and health-care providers [3]. 
 
Economic studies in MND, including cost analyses, preference elicitation and economic 
evaluations, both in the UK and internationally, have a limited evidence base. The extent of 
these limitations has been described in our systematic review of economic studies in MND 
[4]. These studies are restricted in terms of cost measurement, and small samples for 
estimating health utility. There is limited experience of the EuroQoL (EQ)-5D in MND 
populations [5,6], with possible flooring effects in the EQ-5D-3L. In one study [6], EQ-5D-3L 
health utility values decreased as disease severity increased, whereas in the other, health 
states were not mutually exclusive [5]. 
 
The costs of MND to the National Health Service (NHS) in the UK are believed to be high, 
owing to the nature of the disease, but are not well documented within the health 
economic literature [4]. A  study published in 1998,  using expert opinion to estimate 
resource use, provided cost estimates for some less severe health stages which were  higher 
than the most severe stage [7]. In international studies, reported costs have increased as 
severity worsened [4]. 
 
Previous studies in MND have involved attempts to describe and model disease progression 
using clinical staging systems [8-11]. These facilitate analyses of costs and benefits using 
clearly defined clinical health states, and provide a structure for simulation models, such as 
Markov models [12], for estimating cost-effectiveness. The two most commonly used 
clinical staging systems in MND are the Kings [10] and the Milano-Torino (MiToS) staging 
systems [11]. The Kings system is structured around clinical involvement of bulbar and limb 
areas and nutritional or respiratory failure, whereas the MiToS system is focused on loss of 
independence across the domains of bulbar, gross motor, fine motor and respiratory 
function.  
 
The Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) [13] is the 
most commonly used disability measure in MND clinical research and is recommended for 
capturing changes in functionality along the disease course [14,15]. The Kings system was 
developed for patients to be staged by clinicians but it can also be derived from the ALSFRS-
R with good accuracy [16], whereas the MiToS staging system is based directly on ALSFRS-R 
responses. The fact that both of these staging systems can be used with ALSFRS-R data 
makes them particularly useful in the analysis of clinical trials, which routinely use the 
ALSFRS-R as a primary outcome measure.  
 
We aimed to contribute to the evidence-base of economic studies in MND by presenting 
costs, and health state utilities based on the EQ-5D-5L [17] and the ALS utility index [18], 
defined by both Kings and MiToS staging. This study provides evidence for future economic 
evaluations in MND to inform health technology assessment and decision making within the 
UK National Health Service. , We provide valuable information on how MND impacts upon 
patients’ quality of life and NHS costs at various clinical stages, by using a range of health 




Data were obtained from the Trajectories of Outcomes in Neurological Conditions (TONiC) 
study conducted in the UK. TONiC is an ongoing longitudinal cohort study which, at the time 
of this study, had recruited patients from 22 MND clinics within the UK. The TONiC study is 
primarily aimed at assessing factors affecting patients’ quality of life and their experience of 
MND [19]. Patients attending MND clinics are given questionnaires at various time points  
for postal return; at 0, 4, 9, 14, 18, 27 and 60 months from their inclusion in the TONiC 
study. The health economic components include a resource use questionnaire, which was a 
modified version of a questionnaire used in epilepsy [20] (available from the Database of 
Instruments for Resource Use Measurement [21]) and the EQ-5D-5L questionnaire.  Baseline 
responses were used in the present study as longitudinal data had not matured sufficiently 
at the time of analysis, which resulted in this study being cross-sectional in nature.  
 
The TONiC study was approved in the UK by NRES Committee North West – Greater 
Manchester West (reference number 11/NW/0743) and informed consent was obtained 
from the patients involved.  
 
Demographic and clinical characteristics  
Respondents reported their age and gender. MND onset type (limb, bulbar, respiratory or 
unknown) was determined by a clinician familiar with each patient’s case.  
 
Disease-specific measure 
The ALSFRS-R, which was completed by study participants, comprises of 12 items, each 
scored from 0 (worse state) to 4 (best state with less disability) [13]. These items are 
commonly divided to 3 distinct domains; bulbar (items 1-3), motor (items 4-9) and 
respiratory (items 10-12) [22]. We used the ALSFRS-R to assign patients to Kings and MiToS 
states [10,11]. 
 
Health utility  
Patents completed the EQ-5D-5L which comprises of five domains; mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression [17]. Each of these domains has five 
levels indicating worsening health, from having no problems, to having severe problems. 
Responses to the EQ-5D-5L were used to calculate health utilities. Each possible 
combination of responses to the five questions of the EQ-D5-5L is associated with a health 
utility value, based on time trade-off valuations from a representative sample of the general 
public in England [17]. We also present results from the EQ-5D-visual analogue scale (EQ-5D 
VAS), which complements the main EQ-5D-5L questionnaire and measures self-reported 
health values as indicated on a vertical scale. 
 
The ALS Utility Index (ALSUI) was calculated from responses to the ALSFRS-R [18]. This 
measure is the first such to present a disease-specific, preference-based index in MND, 
based on scoring determined from a standard gamble experiment taken by members of the 
general public in the United States. The ALSUI algorithm attaches a preference weighting to 
ALSFRS-R items 1, 6, 8, 10 and 12, to obtain a single index value ranging from 0 (worse 
possible state) to 1 (best possible state) [18]. 
 
Clinical staging 
As Kings staging is based on clinical observation, we used a mapping algorithm which 
estimates Kings stages with 92% accuracy [16]. Kings stages 1,2,3 are allocated by counting 
the number of times a patient shows any loss (any score below 4 on relevant items) in the 
domains of bulbar, upper limbs and lower limbs; involvement of any one region leads to 
stage 1, two regions stage 2 and so on.  Patients with respiratory or swallowing failure are 
allocated to stage 4.   
 
We also allocated patients in this study to MiToS system stages [11]. This was done using 
the ALSFRS-R, from which the MiToS system was developed. All MiToS stages are allocated 
on counts of losses in independence in domains of bulbar, gross motor, fine motor and 
respiratory function. Loss of independence in one domain is stage 1, in two domains stage 2 
and so on.  If no loss of independence has occurred, patients are allocated to stage 0.  
 
Resource use and cost  
The resource use questionnaire asked respondents about their use of NHS resources, 
including medicines, primary and community care, hospital clinic visits and inpatient stays, 
tests and investigations, within the previous 3 months. Unit costs were sourced from NHS 
reference costs [23] and the Personal Social Services Research Unit (PSSRU) [24,25]. All costs 
were inflated to 2017 values, where applicable, using the hospital and community health 
services (HCHS) index PSSRU [24]. The full disaggregated data on items and unit costs are 
presented in the Supplementary Appendix. 
 
Missing data 
Patients were omitted from the analysis of health utility if they had not completed the EQ-
5D-5L in full, and from the cost analysis if they had not answered all required questions on 
the resource use questionnaire. Further to this, patients who did not complete the ALSFRS-R 
in full were also excluded from the analysis, as they could not be staged according to the 
Kings or MiToS staging systems.  
 
Statistical analysis 
95% Confidence intervals (CI) were estimated using non-parametric bootstrapping, with 
2000 replications with replacement to account for the skewed nature of cost and health 
utility data.  Generalized Linear Models (GLM) with a Gamma log link were used to estimate 
the influence of certain variables, including disease staging, on total patient costs. Data 
management was undertaken in Excel 2016 (Microsoft, Washington, United States) and all 
analyses were carried out in R (Vienna, Austria) [26]. 
  
Results  
Description of data  
958 patients received posted questionnaires, of which 636 (66.4%) were returned. Forty-
one of the questionnaires returned were not sufficiently completed. Health utility data were 
therefore available from 595 patients, and of these 584 patients also provided cost 
information, meaning cost data were available for 98.1% of patients who were staged. Table 
1 presents the characteristics of the participants for both health utility and cost analyses. 
The 11 patients who had completed EQ-5D-5L and ALSFRS-R questionnaires, but had failed 
to complete the resource use questionnaire, had comparable characteristics to those who 
had completed all three questionnaires. Patients in the sample were of similar age, gender 
distribution and MND onset type, to those previously reported in MND populations [27]. 
 
Health utility by MND stage and disease onset type 
Table 2 shows the distributions of EQ-5D-5L domains by model and health state. The “usual 
activities” EQ-5D-5L domain was most affected by MND, as it had the highest proportion of 
severe (level 5) responses and any problems (levels 2-5) across all clinical stages. Conversely, 
the least affected domain on the EQ-5D-5L questionnaire was “anxiety/depression” across 
all clinical stages, based on the same metrics, with the exception of patients in MiToS stage 
3.   
 
Mean (95% CI) health utility scores for the entire sample were EQ-5D-5L 0.57 (0.55, 0.59), 
EQ-5D VAS score 60 (58, 62), and ALS utility Index 0.40 (0.38, 0.42). EQ-5D-5L health utility 
decreased with increasing clinical severity across both the Kings and MiToS systems. For 
Kings staging, health utility reduced from 0.76 (95% CI 0.71, 0.80) in stage 1, to 0.50 (0.45, 
0.54) in stage 4 (Table 3). In the MiToS staging, mean health utility of stage 0 was 0.71 (95% 
CI 0.69, 0.73) but reduced to 0.25 (0.07, 0.42) in stage 4. The measures of ALSFRS-R total 
score, ALSFRS-R domains, ALSUI and EQ-5D VAS all reduced through progressively worse 
clinical stages. ALS utility index values were much lower for all stages across both systems 
than the values for EQ-5D-5L. This result was more prominent for the most severe states in 
both models, with Kings stage 4 mean EQ-5D-5L health utility at 0.50 (0.45, 0.54) and ALSUI 
at 0.24 (0.21, 0.27); and MiToS stage 4 EQ-5D-5L health utility of 0.25 (0.07, 0.42) and ALSUI 
utility of 0.07 (0.07, 0.08).  
 
EQ-5D-5L health utility tended to be higher with bulbar onset MND at 0.68 (95% CI 0.64, 
0.72), compared to either limb 0.53 (0.49, 0.57) or respiratory onset, 0.53 (0.35, 0.71) 
(Supplementary Appendix). This was despite the mean ALSFRS-R total score being higher in 
patients with limb onset MND in our study than in patients with bulbar onset.   
 
Resource use and costs by MND stage and disease onset type 
Seventy-seven (13.2%) patients experienced at least one inpatient stay during a 3-month 
period (Table 4). Inpatient stays were most frequent in Kings stage 4 (0.45) and MiToS stage 
1 (0.40). Kings stage 4 was associated with more resource use in all categories compared 
with other stages, except tests and investigations. The mean number of home visits by 
doctors and nurses was higher for Kings stage 4 (0.68 and 4.35, respectively) than other 
Kings stages; higher levels of home care were also evident in patients in MiToS stage 4 (15.2 
nurse home visits and 2.2 doctor home visits) than in less severe MiToS stages (ranging 
between 0.61 and 5.38 nurse home visits, and 0.43 and 1.17 doctor home visits). 
 
The total costs per patient over a 3-month period were £1,889 (95% CI £1,596, £2,214), 
ranging from £53 to £39,884 (Table 5; Figure 1). Overnight inpatient stays made up 35.8% of 
total costs, making it the single largest cost category, while community costs contributed 
14.2% of total costs.  
 
Kings stages showed progressively higher mean costs with advancing disease, ranging from 
£1,096 (95% CI £757, £1,240) in stage 1 to £3,311 (£2,666, £4,151) in stage 4 (Figure 1). The 
association of MiToS staging with costs was less clear, with patients categorised in stage 0 
having the lowest cost of £1,115 (£937, £1,130) and stages 1 to 4 having higher costs, with 
the highest cost occurred in stage 2 at £2,889 (£2,190, £3,810). Drug costs were also higher 
for Kings stage 4 than other Kings stages; and lower for stage 0 than other stages based on 
MiToS stages. Secondary care costs were higher than primary care costs for patients in all 
states, with the exception of those in MiToS stage 4. Bulbar onset patients had higher costs 
in every cost category compared to other onset types.  
 
Generalized Linear Model regressions indicated that Kings stages 3 and 4, and MiToS Stages 
1 and 2, respectively, were significant in explaining variability in total costs (Table 6). Bulbar 
onset was associated with higher costs in the MiToS system, but neither age nor gender 
contributed significantly to costs in either model.  
 
Comparison of Kings and MiToS staging  
There was moderate correlation (Spearman’s rank coefficient of 0.58), in patient 
categorisation between the Kings and MiToS staging systems (Supplementary Appendix).  
Within any given Kings stage, health utility scores decreased with increasing MiToS stage. 
For example, patients in Kings stage 4 had mean health utility scores ranging from 0.25 
(MiToS stage 4) to 0.67 (MiToS Stage 1).  
 
Discussion  
This analysis of health utility and costs by clinically defined health stages provides empirical 
evidence of the impact of the progressive nature of MND, and data to support future 
economic evaluations in MND. This study benefitted from using two commonly used health 
staging systems, Kings and MiToS staging, and represents the most comprehensive health 
utility and cost study in MND. 
 
The mean, 3-month NHS costs of £1,889 is significantly higher than estimates for some 
other neurodegenerative conditions (e.g. £529 for patients with Parkinson’s disease [28]) 
and comparable to others (e.g. £1,880 for patients with Huntington’s disease [29]). The 
comparison between our study and earlier estimates of the costs of MND in the UK is 
difficult because of difference in methodology and staging systems used. However, our 
study appears to have a higher cost for the most severe Kings state, (£3,311 over 3 months) 
compared to the most severe state in Munsat et al [7] (£5,825 over 12 months), after 
accounting for inflation. This could be attributed to our study accounting for a wider scope 
of costs such as home-based care, and using resource use information from patient survey 
questions rather than relying on expert opinion, which is less reliable [7]. A substantial 
portion of costs (40%) in our study population related to hospital admissions, which 
occurred at a rate of 92 per 100 patient-years. This reflects the gravity of MND, and the 
frequent need of patients for specialist medical care. 
 
The Kings staging system showed that patients incurred increased costs with more severe 
health stages: Kings stage 4 had significantly higher costs than other Kings stages, which is 
likely a result of this stage being defined by nutritional and respiratory failure, and survival 
requiring gastrostomy feeding or respiratory support such as non-invasive ventilation. 
Patients in Kings stages 1 to 3 also show increasing costs, which was expected as these 
stages reflect an increasing number of body regions affected by the condition. Higher costs 
in MiToS stage 1 compared to 0 may be explained by this involving the first loss of 
independence.  MiToS stages 2 to 4 were associated was smaller marginal increased costs, 
as once independence has been lost in one domain, other losses may not result in increased 
healthcare costs, although it should be noted that the number of patients in these 
categories were relatively low. 
 
The mean health utility of patients in the sample was 0.57, with individual responses across 
the full range of the EQ-5D-5L index. The largest health utility decrement between 
consecutive states was from Kings stage 1 to stage 2, indicating that losing functioning in a 
second domain may impact health-related quality of life more than subsequent additional 
losses, and suggesting a diminishing marginal negative impact on health utility with disease 
severity. Health utility was lower for people in more severe stages compared to less severe 
stages in both the Kings and MiToS systems, reflecting the higher percentages of more 
severe responses across the 5 domains of the EQ-5D-5L in more advanced stages. It should 
be noted, however, that as the data are based on a cross-sectional analysis, inferences on 
longitudinal effects are speculative. Bulbar onset patients in our study tended to have 
higher EQ-5D-5L health utility than patients with limb or respiratory onset. This result may 
be in part due to the domains featured in the EQ-5D-5L, which could be expected to capture 
losses in mobility, which is impacted more in limb onset, than symptoms that are more 
prominent in bulbar onset.   
 
Health state utilities by Kings staging have been reported previously using the EQ-5D-3L [6]. 
Our reporting of EQ-5D-5L utilities may mitigate ceiling/floor effects, although insufficient 
data has been presented in previous studies to evaluate this. Health utilities reported using 
the EQ-5D-3L are considerably lower across all King’s health states (1 to 4) when compared 
to our study (0.65, 0.53, 0.41 and 0.27 using EQ-5D-3L, compared to 0.71, 0.60, 0.53 and 
0.50, using EQ-5D-5L). This could be attributed to the revised tariffs used in our study, but 
also to the easing of flooring effects. EQ-5D VAS scores showed better agreement between 
our study and Jones et al. [6], with the two studies having comparable values for all Kings 
states. This highlights the differences in structure between the EQ-5D-3L and 5L 
questionnaires and could provide evidence to suggest the 5 level questionnaire is more 
sensitive to changes in quality of life in people with MND as the disease progresses.  
 
Differences between the Kings and MiToS staging systems in terms of patient distribution, 
costs and health utility can be explained by their construct [30]. In the Kings staging system, 
the focus is on disease spread through upper and lower limbs as well as bulbar regions. 
Disability in these regions is defined as any loss (any score below 4) in certain ALSFRS-R 
items. Stages 1, 2 and 3 are assigned by counts of these disabilities. The model also has a 
mechanism which assigns patients with swallowing or respiratory failure to the most severe 
stage 4. In contrast, the MiToS system is structured around loss of independence in domains 
of bulbar, gross motor, fine motor and respiratory loss. Loss of independence in these 
domains requires respondents to score a 0 or 1 on certain ALSFRS-R items. These scores are 
low as all items cover a range from 0 to 4. Patients are assigned stages based on a count of 
affected domains. No mechanism within the MiToS system allocates patients to the most 
severe stage in the MiToS model if nutritional or respiratory failure occurs.  
 
Limitations of our study include the low number of patients in stages 3 and 4 of the MiToS 
staging system, and no estimates for caregiver and other indirect costs which are likely to be 
high [31,32]. Further to this, our study presented cross-sectional results rather than 
longitudinal and used episode costs for inpatient admissions as the length of hospital stay of 
patients was unknown.  
 
In conclusion, while it is well understood that MND lowers patients’ health-related quality of 
life and is associated with substantial costs to health care systems, the evidence presented 
herein provides a basis for future health economic analyses of interventions for MND. Our 
use of two well established health staging systems, Kings and MiToS, allows for costs and 




1. van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet  
2017;390(10107):2084-98. 
2. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis.  N Engl J Med. 2017;377(2):162-
72. 
3. Oh J, An JW, Oh SI, et al. Socioeconomic costs of amyotrophic lateral sclerosis according 
to staging system. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3-4):202-
8.  
4. Moore A, Young CA, Hughes DA. Economic Studies in Motor Neurone Disease: A 
Systematic Methodological Review. Pharmacoeconomics. 2017;35(4):397-413. 
5. Kiebert GM, Green C, Murphy C, et al. Patients’ health-related quality of life and utilities 
associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci. 
2001;191(1-2):87-93. 
6. Jones AR, Jivraj N, Balendra R, et al. Health utility decreases with increasing clinical stage 
in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 
2014;15(3-4):285-91. 
7. Munsat TL, Rivière M, Swash M, et al. Economic burden of amyotrophic lateral sclerosis 
in the United Kingdom. J Med Econ. 1998;1(1-4):235-45. 
8. Bravver E, Sanjak M, Brooks B. Disease Severity and Disease Trajectory of Amyotrophic 
Lateral Sclerosis (ALS) Patients at Frist Clinic Visit Measured Prospectively with "ALS 
Dashboard" – A Six-Domain (Cognition, Affect, Bulbar, Respiratory, Arm, Leg) Staging 
System – Comparison of Two Cohorts (P07.088). Neurology. 2013;80(Supplement 
7.088). 
9. Rivere M, Meininger V, Zeisser P, et al. An analysis of extended survival in patients with 
amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55(4):526-8.  
10. Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic 
lateral sclerosis. Brain. 2012;135(Pt 3):847-52. 
11. Tramacere I, Dalla Bella E, Chiò A, et al. The MITOS system predicts long-term survival in 
amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(11):1180-5. 
12. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. 
Pharmacoeconomics. 1998;13(4):397-409. 
13. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating 
scale that incorporates assessments of respiratory function. BDNF ALS Study Group 
(Phase III). J Neurol Sci 1999;169(1-2):13-21. 
14. Leigh PN, Swash M, Iwasaki Y, et al. Amyotrophic lateral sclerosis: a consensus viewpoint 
on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor 
Neuron Disord 2004;5(2):84-98. 
15. Rooney J, Burke T, Vajda A, et al. What does the ALSFRS-R really measure? A longitudinal 
and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J 
Neurol Neurosurg Psychiatry 2017;88:381-5. 
16. Balendra R, Jones A, Jivraj N, et al. Use of clinical staging in amyotrophic lateral sclerosis 
for phase 3 clinical trials. J Neurol Neurosurg Psychiatry. 2015;86(1):45-9. 
17. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: 
An EQ-5D-5L value set for England. Health Econ. 2018;27(1):7-22. 
18. Beusterien K, Leigh N, Jackson C, et al. Integrating preferences into health status 
assessment for amyotrophic lateral sclerosis: the ALS Utility Index. Amyotroph Lateral 
Scler Other Motor Neuron Disord. 2005;6(3):169-76. 
19. Trajectories of Outcomes in Neurological Conditions (TONiC). 
https://tonic.thewaltoncentre.nhs.uk/tonic-mnd (Accessed 29th April 2018). 
20. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of 
valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an 
unblinded randomised controlled trial. Lancet. 2007;369(9566):1016-26. 
21. Database of Instruments for Resource Use Measurement (DIRUM). 
http://www.dirum.org (Accessed 19th September 2018). 
22. Franchignoni F, Mora G, Giordano A, et al. Evidence of multidimensionality in the 
ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. J 
Neurol Neurosurg Psychiatry. 2013;84:1340-5. 
23. Department of Health and Social care (2017). NHS reference costs 2016-17.  
24. Curtis L, Burns A. (2017) Unit Costs of Health and Social care 2017, University of Kent, 
Canterbury. https://doi.org/10.22024/UniKent/01.02/65559 (Accessed 30th October 
2018). 
25. Curtis L. (2010) Unit Costs of Health and Social Care 2010, Personal Social Services 
Research Unit, University of Kent, Canterbury.  
26. R Core Team (2013). R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/ 
(Accessed 30th October 2018). 
27. Chiò A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral 
sclerosis: a systematic review of the published literature. Neuroepidemiology 
2013;41(2):118-30. 
28. Gumber A, Ramaswamy B, Ibbotson R, Ismail M, Thongchundee O, Harrop D, Allmark P, 
Rauf A. Economic, Social and Financial Cost of Parkinson's on Individuals, Carers and 
their Families in the UK. Project Report. Centre for Health and Social Care Research, 
Sheffield Hallam University. 2017. http://shura.shu.ac.uk/15930/ (Accessed 30th 
October 2018).  
29. Jones C, Busse M, Quinn L, et al. The societal cost of Huntington's disease: are we 
underestimating the burden? Eur J Neurol. 2016;23(10):1588-90. 
30. Fang T, Al Khleifat A, Stahl D, et al. Comparison of the King’s and MiToS staging systems 
for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3-4):227-32. 
31. Galvin M, Corr B, Madden C, et al. Caregiving in ALS – a mixed methods approach to the 
study of burden. BMC Palliative Care. 2016;15(1):81. 
32. Galvin M, Carney S, Corr B, et al. Needs of informal caregivers across the caregiving 




Table 1 Characteristics of samples used for the health utility and cost analysis 
 
  Health utility sample Cost sample * 
Sample size   595 584 
Age in years Mean (SD) 65.07 (10.89) 65.05 (10.91) 
Female  n (%) 232 (39.0) 230 (39.21)  
Months since diagnosis Mean (SD) 26.54 (38.8) 26.59 (38.9) 
MND Onset Type  n (%)   
Limb  404 (69.9) 400 (68.5) 
Bulbar   159 (26.7) 155 (26.5)  
Respiratory   11 (2.5) 11 (1.9)  
EQ-5D-5L Utility  Mean (95% CI) 
Median (IQR) 
0.57 (0.55, 0.59) 
0.61 (0.38, 0.78) 
0.57 (0.55, 0.59) 
0.62 (0.38, 0.79) 
EQ-5D VAS  Mean (95% CI) 
Median (IQR) 
60 (58, 62) 
60 (45, 75) 
60 (58, 62) 
61 (45, 75) 
ALSFRS-R Index  Mean (95% CI) 
Median (IQR) 
31.95 (31.19, 32.55) 
33 (27, 38) 
31.96 (31.16, 32.58) 
33 (27, 38) 
ALS Utility Index  Mean (95% CI) 
Median (IQR) 
0.40 (0.38, 0.42) 
0.36 (0.27, 0.58) 
0.40 (0.38, 0.42) 
0.36 (0.27, 0.59) 
Kings Staging n (%)   
Stage 1   89 (15.0) 86 (14.7) 
Stage 2  135 (22.7) 131 (22.4) 
Stage 3  206 (34.6) 201 (34.4) 
Stage 4  162 (27.3) 160 (27.4)  
MiToS Staging n (%)   
Stage 0  301 (50.59) 296 (50.69) 
Stage 1   198 (33.28) 195 (33.39) 
Stage 2  73 (12.69)  72 (12.33) 
Stage 3  18 (3.03) 16 (2.74)  
Stage 4   5 (0.84)  5 (0.86)  
 
*Cost analysis cohort was a subset of the health utility study cohort. 
*SD = standard deviation, CI = confidence interval, IQR = interquartile range.   
Table 2 EQ-5D-5L domain responses by health stage and system  
 
 EQ-5D-5L domain 
Response Level  Mobility  Self-Care Usual Activities  Pain/Discomfort  Anxiety/Depression  
Full sample  
(N= 595) 
n (%) n (%) n (%) n (%) n (%) 
Level 1 99 (16.6) 118 (19.8) 53 (8.9) 179 (30.1) 268 (45.0) 
Level 2 81 (13.6) 152 (25.6) 117 (19.7) 213 (35.8) 203 (34.1) 
Level 3 157 (26.4) 162 (27.2) 174 (29.2) 161 (27.1) 98 (16.5) 
Level 4 152 (25.5)  71 (11.9) 118 (19.8) 37 (6.2) 20 (3.4) 
Level 5 106 (17.8) 92 (15.5) 133 (22.4) 5 (0.9) 6 (1.0) 
Some Problems 496 (83.3) 477 (80.2) 542 (91.1) 416 (69.9)  327 (55.0) 
      
Kings stage 1 (N= 89) 
Level 1 49 (55.1) 42 (47.2) 25 (28.1) 46 (51.7) 53 (59.5) 
Level 2 7 (7.9) 23 (25.8) 27 (30.3) 26 (29.2) 29 (32.6) 
Level 3  12 (13.5) 16 (17.98)  16 (18.0) 16 (18.0) 6 (6.7) 
Level 4 15 (16.9)  6 (6.4)  11 (12.4) 1 (1.1) 1 (1.1) 
Level 5  6 (6.7) 2 (2.2) 10 (11.3) 0 (0) 0 (0) 
Some Problems 40 (44.9) 63 (52.8) 64 (72.0) 43 (48.3) 36 (40.4) 
      
Kings stage 2 (N= 135) 
Level 1 22 (16.3) 28 (20.7) 11 (8.2) 43 (31.9) 66 (48.9) 
Level 2  28 (20.7) 40 (29.6) 33 (24.4) 47 (34.8) 45 (33.3) 
Level 3 37 (27.4) 34 (25.2) 44 (32.6) 33 (24.4) 16 (11.9) 
Level 4  26 (19.3) 16 (11.9) 28 (20.7) 10 (7.4) 5 (3.7) 
Level 5  21 (15.6) 16 (11.9) 18 (13.3) 1 (0.74) 2 (1.5) 
Some Problems 113 (83.7) 107 (79.3) 124 (91.9) 92 (68.1) 69 (51.1) 
      
Kings stage 3 (N= 206) 
Level 1 6 (2.9) 22 (10.7) 6 (2.9) 43 (20.9) 86 (41.7) 
Level 2 30 (14.6) 57 (27.7) 36 (17.5) 76 (36.9) 75 (36.4) 
Level 3 66 (32.0) 65 (31.6) 66 (32.0) 72 (35.0) 39 (18.9) 
Level 4 63 (30.6) 31 (15.0) 47 (22.8) 11 (5.4) 3 (1.5) 
Level 5 40 (19.5) 30 (14.6) 50 (24.3) 3 (1.5) 2 (1.0) 
Some Problems 200 (97.1) 184 (89.3) 200 (97.1) 163 (79.06) 120 (58.3) 
      
Kings stage 4 (N= 162) 
Level 1 19 (11.7) 24 (14.8) 9 (5.6) 45 (27.8) 61 (37.7) 
Level 2 17 (10.5) 31 (19.1) 21 (13.0) 61 (37.7) 53 (32.7) 
Level 3 40 (24.7) 46 (28.4) 48 (29.6) 40 (24.7) 35 (21.6) 
Level 4 48 (29.6) 18 (11.1) 31 (19.1) 15 (9.3) 11 (6.8) 
Level 5 38 (23.5) 43 (26.5) 53 (32.7) 1 (0.6) 2 (1.2) 
Some Problems 143 (88.3) 138 (85.2) 153 (94.4) 117 (72.2) 101 (62.4) 
      
MiToS stage 0 (N= 301) 
Level 1 79 (26.3) 94 (31.2) 46 (15.3) 113 (37.5) 154 (51.2) 
Level 2 54 (17.9) 119 (39.5) 96 (31.9) 102 (33.8) 107 (35.6) 
Level 3 96 (31.9) 75 (24.9) 101 (33.6) 71 (23.6) 35 (11.6) 
Level 4 88 (29.2) 13 (4.3) 39 (13.0) 14 (4.6) 5 (1.7) 
Level 5 6 (2.0) 0 (0) 22 (7.3) 1 (0.3) 0 (0) 
Some Problems 222 (73.4) 207 (68.8) 255 (84.7) 188 (62.5) 147 (48.8) 
      
MiToS stage 1 (N=198) 
Level 1 16 (8.9) 22 (11.1)  9 (4.6) 40 (20.2) 84 (42.4) 
Level 2 22 (11.1) 26 (13.1) 16 (8.1) 75 (37.9) 63 (31.8) 
Level 3 44 (22.2) 60 (30.3) 60 (30.3)  66 (33.3) 37 (18.7) 
Level 4 60 (30.3)  41 (20.7)  57 (28.8) 14 (7.1) 7 (3.5) 
Level 5 54 (27.3) 47 (23.7) 54 (27.3) 1 (0.5) 3 (1.5) 
Some Problems 182 (91.9) 176 (88.9) 189 (95.5)  158 (80.0) 114 (57.6)  
      
MiToS stage 2 (N= 73) 
Level 1 4 (5.5) 3 (4.1) 1 (1.4) 21 (28.8)  24 (32.9) 
Level 2 5 (6.9) 4 (5.5)  5 (6.9)  26 (35.6)  29 (39.7)  
Level 3 11 (15.1) 21 (28.8) 10 (13.7)  15 (20.6)  15 (20.6)  
Level 4 17 (23.3)  15 (20.6)  19 (26.0)  8 (11.0)  4 (5.5)  
Level 5 36 (49.3)  36 (49.3) 38 (52.1) 3 (4.1)  1 (1.4) 
Some Problems 69 (94.5)  70 (95.9)  72 (98.6)  52 (71.2)  49 (67.1)  
      
MiToS stage 3 (N=18) 
Level 1 0 (0) 0 (0) 0 (0) 4 (22.2) 3 (16.7) 
Level 2 1 (5.6) 2 (11.1) 1 (5.6) 7 (38.9) 5 (27.8) 
Level 3 3 (16.7) 5 (27.8) 2 (11.1) 6 (33.3) 8 (44.4) 
Level 4 7 (38.9) 1 (5.6) 2 (11.1) 1 (5.6) 2 (11.1) 
Level 5 7 (38.9) 10 (55.6) 13 (72.2) 0 (0) 0 (0) 
Some Problems 18 (100) 18 (100) 18 (100)  14 (77.8) 15 (83.3) 
      
MiToS stage 4 (N= 5) 
Level 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Level 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Level 3 1 (20) 1 (20) 1 (20) 1 (20) 2 (40) 
Level 4 2 (40) 0 (0) 0 (0) 1 (20) 1 (20) 
Level 5 2 (40) 4 (80) 4 (80) 3 (60) 2 (40) 
Some Problems 5 (100) 5 (100) 5 (100) 5 (100) 5 (100) 
 
‘Some problems’ are defined as any response from level 2 to level 5 
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Scale range of included measures (minimum to maximum): EQ-5D-5L -0.21 to 1; EQ-5D VAS 
0 to 1; ALSFRS-R Index 0 to 48; ALSFRS-R Bulbar 0 to 12; ALSFRS-R Gross Motor 0 to 24; 




Table 4 Resource use by health stage and system  
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CT Scan  
 












































































































































































Abbreviations: CT Computerised Tomography; MRI Magnetic Resonance Imaging; EMG Electromyography 
Table 5 Direct healthcare costs by health stage and system, mean, £ sterling (95% CI) 
 
  Kings MiToS 
Category Full Sample  
 
Stage 1 Stage 2 Stage 3 Stage 4 Stage 0 Stage 1  Stage 2 Stage 3 Stage 4 





















































































































































Table 6 Generalized Linear Models, showing influence of disease staging, onset type, and 
demographic variables on total costs 
 
Variable  Coefficient (SE) Relative increase in 




Constant 7.02 (0.53)  <0.01  
Kings 2 0.36 (0.26) 1.43 (1.11, 1.86) 0.17 
Kings 3 0.50 (0.25) 1.65 (1.28, 2.12) 0.05 
Kings 4 1.24 (0.26) 3.45 (2.66, 4.48) <0.01  
Bulbar onset 0.07 (0.19) 1.07 (088, 1.30) 0.25 
Respiratory onset -0.67 (0.57) 0.51 (0.29, 0.90) 0.71 
Gender (male = 1) 0.01 (0.16)  1.01 (0.97, 1.05) 0.98 
Age (years) 0.001 (0.01) 1.001 (0.999, 1.002)  0.88 
Time since diagnosis (months)  -0.01 (0.002) 0.99 (0.98, 1.0) <0.01  
MiToS Staging 
Constant 7.13 (0.45)  <0.01  
MiToS 1 0.84 (0.15) 2.32 (1.99, 2.69)  <0.01  
MiToS 2 0.98 (0.22)  2.66 (2.14, 3.32) <0.01 
MiToS 3 0.92 (0.41) 2.51 (1.67, 3.78) 0.07 
MiToS 4 0.79 (0.75)  2.20 (1.04, 4.66)  0.29 
Bulbar onset 0.32 (0.16) 1.38 (1.17, 1.62)  0.04 
Respiratory onset -0.32 (0.51) 0.73 (0.44, 1.12)  0.53 
Gender (male = 1) 0.01 (0.04)  1.01 (0.97, 1.05)  0.97 
Age  0.001 (0.01)  1.001 (1.0, 1.002)  0.98 
Time since diagnosis (months) -0.01 (0.002)  0.99 (0.98, 1.0) <0.01  
 
*Increase relative to Kings stage 1 or MiToS stage 0 (e.g. Kings stage 3 is associated with a 
65% increase in costs relative to Kings stage 1). 
  





Parts A and B show costs and utilities, respectively, by Kings staging system whereas parts C 
and D show the same information for MiToS staging system 
 
